Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial

被引:17
|
作者
Onichimowski, Dariusz [1 ]
Bedzkowska, Anita [2 ]
Ziolkowski, Hubert [3 ]
Jaroszewski, Jerzy [3 ]
Borys, Michal [4 ]
Czuczwar, Miroslaw [4 ]
Wiczling, Pawel [2 ]
机构
[1] Univ Warmia & Mazury, Dept Anesthesiol & Intens Care, Fac Med, Ul Zolnierska 18, PL-10900 Olsztyn, Poland
[2] Med Univ Gdansk, Dept Biopharmaceut & Pharmacodynam, Gdansk, Poland
[3] Univ Warmia & Mazury, Dept Pharmacol & Toxicol, Fac Vet Med, Olsztyn, Poland
[4] Med Univ Lublin, Dept Anaesthesiol & Intens Therapy 2, Lublin, Poland
关键词
Sepsis; Meropenem; Pharmacokinetic modelling; Critically ill; Renal replacement therapy; SEPTIC SHOCK; PHARMACODYNAMICS;
D O I
10.1007/s43440-020-00104-3
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background The primary objective of this study was to develop a population pharmacokinetic model of meropenem, based on the population of critically ill adult patients undergoing CRRT. The secondary one was to examine the relationship between patient characteristics (covariates) and individual PK parameters. Finally, we aimed to perform Monte Carlo simulations to assess the probability of target attainment (PTA) of %T > MIC considering the uncertainty of PK parameters. Materials and methods The study population included 19 adult critically ill patients on CRRT, receiving 1 g of meropenem in 1-h infusions every 8 h. Blood samples were collected prior to (time zero) and 15, 30, 45, 60, 75, 90, 120, 180, 240 and 480 min after the start of meropenem administration. Population nonlinear mixed-effects modeling was conducted using NONMEM software, Fortran, and Wings for NONMEM. Results A two-compartment model was used to describe the available data. Typical values of the central and peripheral volume of distribution, and the CRRT and inter-compartmental clearance for a theoretical patient with 24.6 g/l albumin concertation wereV(1) = 27.9 l,V-2 = 33.7 l,Cl-CRRT = 15.1 l/h, andQ = 21.1 l/h. A significant covariate relationship betweenV(1)and albumin concentration was observed in the data that was described by a power relationship with - 2.87 exponent. Subsequently performed Monte Carlo simulations of the model allowed us to assess the impact of albumin concentration on PTA. The 40%T > 2 mg/l target was reached in more than 90% of subjects after 1-h infusion of 1000 mg q8h and steady-state conditions. The more stringent 100%T > 2 mg/l target requires higher doses and/or longer infusion durations that depend on the albumin concentration. Conclusions The population PK model was successfully developed to describe the time course of meropenem concentrations. The hypoalbuminemia was found to be associated with higher PTA in the CRRT patients after multiple short-term infusions.
引用
收藏
页码:719 / 729
页数:11
相关论文
共 50 条
  • [21] Aminoglycoside Pharmacokinetics in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    Krueger, Chelsea K.
    Bruno, Jeffrey J.
    Tverdek, Frank P.
    Hernandez, Mike
    Abudayyeh, Ala
    ANNALS OF PHARMACOTHERAPY, 2023, 57 (06) : 629 - 636
  • [22] Pharmacokinetics of trimethoprim/sulfametrole in critically ill patients on continuous renal replacement therapy
    Welte, Rene
    Beyer, Rudolph
    Hotter, Johannes
    Broeker, Astrid
    Wicha, Sebastian G.
    Gasperetti, Tiziana
    Ranke, Paul
    Zaruba, Marc-Michael
    Lorenz, Ingo
    Eschertzhuber, Stephan
    Stroehle, Mathias
    Bellmann-Weiler, Rosa
    Joannidis, Michael
    Bellmann, Romuald
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (05) : 1237 - 1241
  • [23] Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients
    Malone, RS
    Fish, DN
    Abraham, E
    Teitelbaum, I
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (11) : 3148 - 3155
  • [24] The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients
    Fiore, Marco
    Peluso, Lorenzo
    Taccone, Fabio Silvio
    Hites, Maya
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2021, 17 (05) : 543 - 554
  • [25] Daptomycin pharmacokinetics in critically ill patients undergoing continuous renal replacement therapy
    Rudiger, Alain
    Rentsch, Katharina
    Maggiorini, Marco
    Corti, Natascia
    CRITICAL CARE MEDICINE, 2011, 39 (05) : 1243 - 1244
  • [26] Population pharmacokinetics of meropenem in critically ill patients
    Rancic, Aleksandar
    Milosavljevic, Milos N.
    Rosic, Nikola
    Milovanovic, Dragan
    Folic, Marko
    Zecevic, Dejana Ruzic
    Petrovic, Nemanja
    Corbic, Mirjana Milojevic
    Dabanovic, Vera
    Jankovic, Slobodan M.
    OPEN MEDICINE, 2024, 19 (01):
  • [27] Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
    He, Sha
    Cheng, Zeneng
    Xie, Feifan
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2022, 16 : 13 - 22
  • [28] Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy
    Xie, Feifan
    Li, Sanwang
    Cheng, Zeneng
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (06) : 1559 - 1566
  • [29] MEROPENEM PHARMACOKINETICS IN CRITICALLY ILL PATIENTS ON CONTINUOUS HEMODIAFILTRATION
    Mochida, Yasuhiro
    Matsumoto, Kana
    Morita, Kunihiro
    Tsutsumi, Daimu
    Ishioka, Kuihiro
    Maesato, Kyouko
    Oka, Machiko
    Moriya, Hidekazu
    Hidaka, Sumi
    Ohtake, Takayasu
    Kobayashi, Shuzo
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2013, 28 : 211 - 211
  • [30] Reply to Beranger et al., "Integration of Continuous Renal Replacement Therapy in a Meropenem Population Pharmacokinetics Model in Critically Ill Children"
    Saito, Jumpei
    Shoji, Kensuke
    Oho, Yusuke
    Kato, Hiroki
    Matsumoto, Shotaro
    Aoki, Satoshi
    Nakamura, Hidefumi
    Ogawa, Takanori
    Hasegawa, Mayumi
    Yamatani, Akimasa
    Miyairi, Isao
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2021, 65 (04)